Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
30 avr. 2024 08h00 HE
|
Recce Pharmaceuticals
Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects, with dosing to start in near weeksR327 dosed at 3,000mg has...
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
17 avr. 2024 08h00 HE
|
Recce Pharmaceuticals
Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaignR327 manufactured under GMP standards in support of current and anticipated clinical...
Recce Pharmaceuticals Provides Business Update
10 avr. 2024 08h00 HE
|
Recce Pharmaceuticals
Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several...
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
09 avr. 2024 20h00 HE
|
Recce Pharmaceuticals
Recce recognized by the United Kingdom Government Innovation Agency among the most promising organizations for the UK AMR Inward Mission 2024Recce chosen as one of 18 organizations globally for its...
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
04 avr. 2024 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State...
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
22 mars 2024 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been...
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
19 mars 2024 08h00 HE
|
Recce Pharmaceuticals
Four healthy subjects dosed with RECCE® 327 at 3,000mg over 20 minutesData received from this cohort will support preparations for a Phase II trial SYDNEY, Australia, March 19, 2024 (GLOBE...
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
14 mars 2024 08h00 HE
|
Recce Pharmaceuticals
The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming daysRECCE® 327 now tested at four infusion times, achieving these...
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
13 mars 2024 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a...
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
12 mars 2024 08h00 HE
|
Recce Pharmaceuticals
SYDNEY, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced...